Form 8-K TG THERAPEUTICS, INC. For: Nov 10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Roth Positive on TG Therapeutics (TGTX) Following Q3 Results; Expects Strong ASH Showing
November 11, 2014 11:31 AM ESTRoth Capital affirms TG Therapeutics (Nasdaq: TGTX) at Buy with a price target of $25 following Q3 results. TGTX posted Q3 loss of $0.51 per share, versus the firm's estimate looking for a loss of $0.32 per share.
Analyst Joseph Pantginis commented, Over the last 12 months, TG has transformed itself with what we consider to be striking clinical data to a pivotal stage company. The... More
